ClinicalTrials.gg
CompletedNCT05357755SUMMITUpdated May 5, 2026Results posted

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

A Phase 2 interventional study of JNJ-77242113 and Placebo in Plaque Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 34 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Psoriasis by Johnson & Johnson — 3 open to participants now, 12 under way, 7 of them phase 3. Psoriasis · Johnson & Johnson.

Enrollment
41st of 58
90 · median 222
Started
2022
with 4 others
Phase 2
12 of 76
none open now
Registered
64th of 76
by date

Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 41st largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2022, is one of 12 in phase 2, and was the 64th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 76 studies in Psoriasis by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Psoriasis by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.

Read the detailed description

The population of people living with moderate to severe psoriasis is approximately 3.5 billion who are mostly managed with topical and conventional therapies. JNJ-77242113, investigational drug, targets the immune responses in the body and skin which impacts diseases, such as psoriasis and psoriatic arthritis and this study evaluates JNJ-77242113 as options of advanced therapies in moderate to severe plaque psoriasis. The hypothesis of this study is that an oral tablet formulation of JNJ-77242113 will result in superior efficacy compared with placebo as determined by the percentage of participants achieving Psoriasis Area and Severity Index (PASI) 75 (greater than or equal to [>=] 75 percentage [%] improvement in PASI) (PASI 75) response at Week 16. The total duration of this study is up to 24 weeks which includes a screening period of less than or equal to (\<=) 4 weeks, a 16-week placebo- controlled treatment period, and a follow-up visit approximately 4 weeks after the last administration of study intervention. Safety assessments include adverse events (AEs) monitoring, clinical safety laboratory assessments, electrocardiograms (ECGs), vital signs, physical examinations, concomitant medication monitoring, pregnancy testing, Columbia Suicide Severity Rating Scale (C-SSRS) and tuberculosis evaluations.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a diagnosis of plaque psoriasis, with or without psoriatic arthritis, for at least 26 weeks prior to the first administration of study intervention
  • Participant has a total Body Surface Area (BSA) greater than or equal to (>=) 10 percentage (%) at screening and baseline
  • Participant has a total Psoriasis Area and Severity Index (PASI) >= 12 at screening and baseline
  • Participant has a total Investigator's Global Assessment (IGA) >= 3 at screening and baseline
  • Participant be a candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion criteria

Exclusion Criteria:

  • Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
  • Participant has current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • Participant have previously received any other therapeutic agent directly targeted to interleukin 23 (including but not limited to guselkumab, tildrakizumab, or risankizumab)
  • Participant has received any therapeutic agent directly targeted to interleukin 17 (IL-17), interleukin 17 receptor (IL-17R) or interleukin 12/23 (IL-12/23) (including but not limited to secukinumab, ixekizumab, brodalumab, or ustekinumab) or has received biological therapy targeting tumor necrosis factor (TNF) (including, but not limited to adalimumab, infliximab, or etanercept) within 12 weeks or 5 half-lives, whichever is longer, of the first administration of study intervention
  • Participant has received proton pump inhibitors (including but not limited to omeprazole, esomeprazole, lansoprazole, rabeprazole, pantoprazole, dexlansoprazole, or zegerid) within 1 week of first administration of study intervention
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Group 1: JNJ-77242113 Dose 1

    Participants will receive JNJ-77242113 Dose 1 as delayed release tablets orally once daily from Week 0 through Week 16.

    Drug: JNJ-77242113

  • Experimental
    Group 2: JNJ-77242113 Dose 2

    Participants will receive JNJ-77242113 Dose 2 as delayed release tablets orally once daily from Week 0 through Week 16.

    Drug: JNJ-77242113

  • Placebo comparator
    Group 3: Placebo

    Participants will receive oral dose of matching placebo once daily from Week 0 through Week 16.

    Drug: Placebo

Interventions

  • JNJ-77242113 will be administered orally as delayed release tablets.

    Also known as: PN-21235,, PN-235

  • DrugPlacebo

    Matching placebo will be administered orally as delayed release tablets.

06

What researchers measure

Primary outcomes

  1. Percentages of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI 75) Score at Week 16

    Percentage of participants who achieved PASI-75 score (greater than or equal to \[\>=\] 75% improvement from baseline in PASI) at Week 16 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

Secondary outcomes

  1. Change From Baseline in PASI Total Score at Week 16

    Change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  2. Percentages of Participants Who Achieved at Least 90% Improvement From Baseline in PASI (PASI 90) Score at Week 16

    Percentage of participants who achieved PASI-90 score (\>=90% improvement from baseline in PASI) at Week 16 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  3. Percentages of Participants Who Achieved 100% Improvement From Baseline in PASI (PASI 100) Score at Week 16

    Percentages of participants who achieved PASI 100- score (100% improvement from baseline in PASI) at Week 16 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  4. Percentage of Participants Who Achieved an Investigator Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>)1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

    Time frame: Week 16

  5. Percentages of Participants Who Achieved an IGA Score of Cleared (0) at Week 16

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>)1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

    Time frame: Week 16

  6. Percent Change From Baseline in Psoriasis-Affected Body Surface Area (BSA) at Week 16

    Percent change from baseline in psoriasis-affected BSA at Week 16 was reported. BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using handprint method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1% BSA. The baseline measurement was defined as the closest measurement taken prior to or at the time of the first study intervention administration date.

    Time frame: Baseline (Week 0), Week 16

  7. Number of Participants With 1 or More Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAE was defined as any adverse event that occurred at or after the initial administration of study intervention. Data included all TEAEs (both serious and non-serious).

    Time frame: From Week 0 through Week 20

  8. Number of Participants With Serious TEAEs

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: results in death, is life threatening, require inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or results in congenital anomaly/birth defect. TEAE was defined as any adverse event that occurs at or after the initial administration of study intervention.

    Time frame: From Week 0 through Week 20

07

Results

Posted May 5, 2026

Participant flow

Participant flow — Overall Study
MilestonePlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QD
Started243134
Completed152232
Not completed992
Withdrew: Lost to follow-up111
Withdrew: Withdrawal by subject761
Withdrew: Other120

Outcome measures

PrimaryPercentages of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI 75) Score at Week 16

Percentage of participants who achieved PASI-75 score (greater than or equal to \[\>=\] 75% improvement from baseline in PASI) at Week 16 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Number · percentage of participants
Percentages of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI 75) Score at Week 16
percentage of participantsPlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QD
Percentages of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI 75) Score at Week 164.241.973.5
Statistical analysis
  • Placebo vs JNJ-77242113 10 mg QD · Cochran-Mantel-Haenszel · p = =0.002
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = <0.001
SecondaryChange From Baseline in PASI Total Score at Week 16

Change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Units on a scale
Change From Baseline in PASI Total Score at Week 16
Units on a scalePlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QD
Change From Baseline in PASI Total Score at Week 16-4.30 ± 6.105-11.56 ± 9.425-16.84 ± 8.278
Statistical analysis
  • Placebo vs JNJ-77242113 10 mg QD · for Repeated Measures (MMRM) · p = =0.002
  • Placebo vs JNJ-77242113 50 mg QD · for Repeated Measures (MMRM) · p = <0.001
SecondaryPercentages of Participants Who Achieved at Least 90% Improvement From Baseline in PASI (PASI 90) Score at Week 16

Percentage of participants who achieved PASI-90 score (\>=90% improvement from baseline in PASI) at Week 16 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Number · percentage of participants
Percentages of Participants Who Achieved at Least 90% Improvement From Baseline in PASI (PASI 90) Score at Week 16
percentage of participantsPlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QD
Percentages of Participants Who Achieved at Least 90% Improvement From Baseline in PASI (PASI 90) Score at Week 16025.852.9
Statistical analysis
  • Placebo vs JNJ-77242113 10 mg QD · Cochran-Mantel-Haenszel · p = =0.007
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentages of Participants Who Achieved 100% Improvement From Baseline in PASI (PASI 100) Score at Week 16

Percentages of participants who achieved PASI 100- score (100% improvement from baseline in PASI) at Week 16 were reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Number · percentage of participants
Percentages of Participants Who Achieved 100% Improvement From Baseline in PASI (PASI 100) Score at Week 16
percentage of participantsPlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QD
Percentages of Participants Who Achieved 100% Improvement From Baseline in PASI (PASI 100) Score at Week 1609.723.5
Statistical analysis
  • Placebo vs JNJ-77242113 10 mg QD · Cochran-Mantel-Haenszel · p = =0.125
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = =0.011
SecondaryPercentage of Participants Who Achieved an Investigator Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>)1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Investigator Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16
percentage of participantsPlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QD
Percentage of Participants Who Achieved an Investigator Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 164.241.973.5
Statistical analysis
  • Placebo vs JNJ-77242113 10 mg QD · Cochran-Mantel-Haenszel · p = =0.002
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentages of Participants Who Achieved an IGA Score of Cleared (0) at Week 16

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>)1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentages of Participants Who Achieved an IGA Score of Cleared (0) at Week 16
percentage of participantsPlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QD
Percentages of Participants Who Achieved an IGA Score of Cleared (0) at Week 16012.929.4
Statistical analysis
  • Placebo vs JNJ-77242113 10 mg QD · Cochran-Mantel-Haenszel · p = =0.071
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = =0.003
SecondaryPercent Change From Baseline in Psoriasis-Affected Body Surface Area (BSA) at Week 16

Percent change from baseline in psoriasis-affected BSA at Week 16 was reported. BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using handprint method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1% BSA. The baseline measurement was defined as the closest measurement taken prior to or at the time of the first study intervention administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in Psoriasis-Affected Body Surface Area (BSA) at Week 16
Percent changePlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QD
Percent Change From Baseline in Psoriasis-Affected Body Surface Area (BSA) at Week 16-0.9 ± 8.26-14.9 ± 15.09-20.1 ± 12.63
Statistical analysis
  • Placebo vs JNJ-77242113 10 mg QD · for Repeated Measures (MMRM) · p = <0.001
  • Placebo vs JNJ-77242113 50 mg QD · for Repeated Measures (MMRM) · p = <0.001
SecondaryNumber of Participants With 1 or More Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAE was defined as any adverse event that occurred at or after the initial administration of study intervention. Data included all TEAEs (both serious and non-serious).

Time frame:
From Week 0 through Week 20
Reported as:
Count of participants · Participants
Number of Participants With 1 or More Treatment-emergent Adverse Events (TEAEs)
ParticipantsPlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QD
Number of Participants With 1 or More Treatment-emergent Adverse Events (TEAEs)141320
SecondaryNumber of Participants With Serious TEAEs

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: results in death, is life threatening, require inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or results in congenital anomaly/birth defect. TEAE was defined as any adverse event that occurs at or after the initial administration of study intervention.

Time frame:
From Week 0 through Week 20
Reported as:
Count of participants · Participants
Number of Participants With Serious TEAEs
ParticipantsPlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QD
Number of Participants With Serious TEAEs002

Adverse events

Collected over From Week 0 through Week 20. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/24 (0%)0/24 (0%)10/24 (41.7%)
JNJ-77242113 10 mg QD0/31 (0%)0/31 (0%)7/31 (22.6%)
JNJ-77242113 50 mg QD0/34 (0%)2/34 (5.9%)11/34 (32.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QD
Radius FractureInjury, poisoning and procedural complications0/240/311/34
NephrolithiasisRenal and urinary disorders0/240/311/34
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QD
Upper Respiratory Tract InfectionInfections and infestations4/241/312/34
Covid-19Infections and infestations0/240/313/34
NasopharyngitisInfections and infestations2/241/311/34
Urinary Tract InfectionInfections and infestations2/241/310/34
PsoriasisSkin and subcutaneous tissue disorders2/240/311/34
Alanine Aminotransferase IncreasedInvestigations0/242/310/34
Aspartate Aminotransferase IncreasedInvestigations0/242/310/34
Blood Glucose IncreasedInvestigations0/242/310/34
Influenza Like IllnessGeneral disorders0/240/312/34
Back PainMusculoskeletal and connective tissue disorders0/240/312/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QDTotal
Mean41.2 ± 12.7841.2 ± 12.3642.2 ± 15.0641.6 ± 13.42
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QDTotal
Female881228
Male16232261
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QDTotal
Hispanic or Latino41510
Not Hispanic or Latino20292978
Unknown or Not Reported0101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QDTotal
American Indian or Alaska Native0000
Asian1124
Native Hawaiian or Other Pacific Islander0000
Black or African American0112
White21273078
More than one race0011
Unknown or Not Reported2204
Region of Enrollment
Region of Enrollment(Participants)PlaceboJNJ-77242113 10 mg QDJNJ-77242113 50 mg QDTotal
CANADA24713
FRANCE1225
GERMANY53412
POLAND511521
SPAIN1124
UNITED STATES10101434
08

Study locations

34 sites
  • Stoll Dermatology
    Beverly Hills, California 90212, United States
  • Northshore University Healthsystem
    Skokie, Illinois 60077, United States
  • Epiphany Dermatology of Kansas, LLC
    Overland Park, Kansas 66210, United States
  • Dermatology Specialists
    Louisville, Kentucky 40241, United States
  • Lawrence J Green MD LLC
    Rockville, Maryland 20850, United States
  • ActivMed Practices and Research
    Beverly, Massachusetts 01915, United States
  • ActivMed Practices and Research
    Portsmouth, New Hampshire 03801, United States
  • Windsor Dermatology, PC
    East Windsor, New Jersey 08520, United States
  • Unity Clinical Research
    Oklahoma City, Oklahoma 73118, United States
  • The Pennsylvania Centre for Dermatology, LLC
    Exton, Pennsylvania 19341, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Arlington Center for Dermatology
    Arlington, Texas 76011, United States
  • Dermatology Research Institute Inc
    Calgary, Alberta T2J 7E1, Canada
  • The Guenther Dermatology Research Centre
    London, Ontario N6A 3H7, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X2, Canada
  • DermEdge Research
    Mississauga, Ontario L4Y 4C5, Canada
  • Toronto Research Centre
    Toronto, Ontario M3H 5Y8, Canada
  • CHRU Brest - Hopital Morvan
    Brest, 29200, France
  • CHU de Grenoble Hopital Albert Michallon
    La Tronche, 38700, France
  • CHU de Nice Hopital de l Archet
    Nice, 06200, France
  • Polyclinique de Courlancy
    Reims, 51100, France
  • Hautarztpraxis
    Bramsche, 49565, Germany
  • Universitatsklinikum Carl Gustav Carus Dresden
    Dresden, 01307, Germany
  • Privatpraxis Dr. Hilton & Partner
    Düsseldorf, 40212, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt am Main, 60590, Germany
  • Universitatsklinikum Schleswig Holstein Campus Lubeck
    Lübeck, 23538, Germany
  • Universitatsklinikum Munster
    Münster, 48149, Germany
  • Universitaetsmedizin Rostock
    Rostock, 18057, Germany
  • Specderm Poznanska sp j
    Bialystok, 15 375, Poland
  • Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
    Krakow, 30 002, Poland
  • Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna
    Lodz, 90-338, Poland
  • Hosp. Univ. de Cruces
    Barakaldo, 48902, Spain
  • Hosp. Univ. San Cecilio
    Granada, 18016, Spain
  • Hosp. Virgen Macarena
    Seville, 41009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Mar 2023, 9 months.

Results were first posted in May 2026, 3 years 1 month after primary completion. A results delay was requested in Mar 2024.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 9 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2022
First posted
May 3, 2022
StartActual
Jun 13, 2022
Primary completionActual
Mar 23, 2023
CompletionActual
Apr 10, 2023
Results delay requested
Mar 21, 2024
Results first posted
May 5, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05357755
Responsible party
Sponsor
First posted
May 3, 2022
Start date
Jun 13, 2022
Primary completion
Mar 23, 2023
Completion
Apr 10, 2023
Results posted
May 5, 2026
Last update
May 5, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icotrokinra

Start the discussion